ClinicalTrials.gg
CompletedNCT04416633Updated Nov 8, 2024Results posted

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

A Phase 4 interventional study of Durvalumab in Unresectable Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca. Completed at 12 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
36th of 94
100 · median 74
Started
2021
with 14 others
Phase 4
2 of 94
1 open now
Registered
62nd of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 36th largest by enrollment, is one of 15 that started in 2021, is one of 2 in phase 4, and was the 62nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)

03

Conditions studied

  • Unresectable Non-small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed, written and dated prior to any study specific Procedures
  2. Male or female aged 18 years or older
  3. As per local prescribing information and in view of positive benefit-risk assessment, patient prescribed Durvalumab treatment as per independent clinical judgment of treating physician for either

Exclusion criteria

Exclusion Criteria:

  1. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
  2. Current or prior use of medication within 14 days before the first dose of study drug, with the exceptions of intranasal and inhaled or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
  3. Prior exposure to any or anti-PD-L1 antibody including durvalumab.
  4. For NSCLC cohort only:

    1. Mixed small cell and non-small cell lung cancer histology
    2. Any unresolved toxicity >Grade 2 from the prior chemoradiation therapy.
    3. Patients with ≥Grade 2 pneumonitis from prior chemoradiation therapy
  5. Active or prior documented disease within the past 2 years, inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), primary immunodeficiency, organ transplant that requires therapeutic immunosuppression, to study drug or any , , tuberculosis.

    NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.

  6. Female patients who are pregnant, breast-feeding or male or female patients of who are not employing an effective method of
  7. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Other
    Durvalumab

    Single arm, Durvalumab , IV

    Drug: Durvalumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number and Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)

    The number and proportion of participants who experienced AEs, SAEs, and AESIs, including interstitial lung disease/pneumonitis-like events and on-study deaths are presented.

    Time frame: Evaluation Phase (Day 1 to 141) to Follow-up Phase (90 days after End of Evaluation Visit [Day 141])

  2. Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)

    The number of events of AEs, SAEs, and AESIs, including interstitial lung disease/pneumonitis-like events and on-study deaths are presented.

    Time frame: Evaluation Phase (Day 1 to 141) to Follow-up Phase (90 days after End of Evaluation Visit [Day 141])

07

Results

Posted Nov 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneDurvalumab
Started100
Completed69
Not completed31
Withdrew: Death1
Withdrew: Disease progression as per investigator's clinical and imaging assessment17
Withdrew: Ae greater than grade 3 related to study drug1
Withdrew: Adverse event6
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryNumber and Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)

The number and proportion of participants who experienced AEs, SAEs, and AESIs, including interstitial lung disease/pneumonitis-like events and on-study deaths are presented.

Time frame:
Evaluation Phase (Day 1 to 141) to Follow-up Phase (90 days after End of Evaluation Visit [Day 141])
Reported as:
Count of participants · Participants
Number and Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)
ParticipantsSafety Population
Any Adverse Event74
Any Serious Adverse Event21
Any Treatment Emergent Adverse Event74
Any Serious Treatment Emergent Adverse Event21
Treatment Emergent Adverse Event related to IMP26
Treatment Emergent Adverse Event leading to IMP discontinuation13
Treatment Emergent Adverse Event leading to Death4
Adverse events of special interest8
PrimaryNumber of Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)

The number of events of AEs, SAEs, and AESIs, including interstitial lung disease/pneumonitis-like events and on-study deaths are presented.

Time frame:
Evaluation Phase (Day 1 to 141) to Follow-up Phase (90 days after End of Evaluation Visit [Day 141])
Reported as:
Number · events
Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESI)
eventsSafety Population
Any Adverse Event267
Any Serious Adverse Event27
Any Treatment Emergent Adverse Event250
Any Serious Treatment Emergent Adverse Event27
Treatment Emergent Adverse Event related to IMP55
Treatment Emergent Adverse Event leading to IMP discontinuation24
Treatment Emergent Adverse Event leading to Death4
Adverse events of special interest8

Adverse events

Collected over Day 1 to Day 230 of the Follow-up Period (ie, up to 8 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab4/100 (4%)21/100 (21%)69/100 (69%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventDurvalumab
DyspnoeaRespiratory, thoracic and mediastinal disorders5/100
DeathGeneral disorders2/100
PyrexiaGeneral disorders2/100
PneumoniaInfections and infestations2/100
FatigueGeneral disorders1/100
PainGeneral disorders1/100
Hepatobiliary diseaseHepatobiliary disorders1/100
Respiratory tract infectionInfections and infestations1/100
SepsisInfections and infestations1/100
Urinary tract infectionInfections and infestations1/100
Most frequent other events
Showing 10 of 88
Most frequent other events
EventDurvalumab
CoughRespiratory, thoracic and mediastinal disorders20/100
PyrexiaGeneral disorders19/100
DyspnoeaRespiratory, thoracic and mediastinal disorders13/100
HypothyroidismEndocrine disorders12/100
Amylase increasedInvestigations6/100
ArthralgiaMusculoskeletal and connective tissue disorders6/100
DiarrhoeaGastrointestinal disorders5/100
AstheniaGeneral disorders5/100
ConstipationGastrointestinal disorders4/100
Chest painGeneral disorders4/100

Baseline characteristics

Enrolled analysis set

Age, Continuous
Age, Continuous(Years)Durvalumab
Mean62.04 ± 10.26
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab
Female18
Male82
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab
INDIAN100
OTHER0
Height
Height(centimeters)Durvalumab
Mean164.44 ± 9.04
Weight
Weight(kilograms)Durvalumab
Mean61.12 ± 11.69
08

Study locations

12 sites
  • Research Site
    Bangalore, 560017, India
  • Research Site
    Bangalore, 560022, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Delhi, 110085, India
  • Research Site
    Faridabad, 121001, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Mohali, 160055, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Mumbai, 400053, India
  • Research Site
    Mumbai, 400056, India
  • Research Site
    New Delhi, 110005, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Oct 2023, 22 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 4, 2020
StartActual
Nov 30, 2021
Primary completionActual
Oct 27, 2023
CompletionActual
Oct 27, 2023
Results first posted
Nov 8, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04416633
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Nov 30, 2021
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023
Results posted
Nov 8, 2024
Last update
Nov 8, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion